Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

JESI, Italy-- (BUSINESS WIRE/AETOSWire): Diatech Pharmacogenetics announced an expansion of its collaboration with Merck ...

Mae pobl sy'n byw yn nhref Pwllheli, Gwynedd yn honni fod gwaith adeiladu "annioddefol" i godi fflatiau gerllaw wedi achosi ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...